Radical cystectomy with or without systemic chemotherapy is considered a standard of care for patients with muscle invasive bladder cancer (MIBC). The purpose of this review is to provide an update on current and recent literature published within the last 12 months reviewing the evidence for use of perioperative chemotherapy for patients with MIBC.
INTRODUCTION
Globally, bladder cancer is the ninth most common cancer with more than 330, 000 cases diagnosed annually and more than 30 000 deaths [1] . Most cases are transitional cell carcinoma (TCC), which will be the focus of this review [1,2 & ,3,4] . Approximately, 20-30% of newly diagnosed patients will have muscle invasive bladder cancer (MIBC) defined as T2-T4 disease [1,2 & ]. Despite surgical management with radical cystectomy, 50% of patients will develop tumor recurrence [4, 5] .
Mounting evidence suggests that perioperative chemotherapy administration for MIBC improves progression-free survival (PFS) and overall survival (OS). Neoadjuvant chemotherapy (NAC) has demonstrated survival benefit in patients with MIBC [6] [7] [8] [9] [10] [11] [12] [13] . Early data to support the use of NAC comes from two Nordic trials [6] [7] [8] , a combined UK Medical Research Council/European Organization of Research and Treatment of Cancer (MRC/EORTC) trial [9] , and the South West Oncology Group (SWOG 8710) intergroup trial from the USA [10] . These studies enrolled patients with T2-T4a N0M0 TCC disease treated with various cisplatin-based chemotherapeutic regimens.
However, the OS benefit with NAC is modest. The MRC/EORTC trial consisting of 976 patients evaluated three cycles of NAC (cisplatin, methotrexate, and vinblastine) followed by radical cystectomy or radiation therapy [9] . In this study, the absolute 5year OS improvement was 5.5% (P ¼ 0.075) [9] . These results were not statistically significant initially but with further follow up, the trial is now positive with an absolute OS benefit of 6% at 10 years [9, 14] . The SWOG 8710 trial was composed of 317 patients and evaluated patients who were randomized to methotrexate, vinblastine, doxorubicin, and cyclophosphamide (MVAC) followed by radical cystectomy versus radical cystectomy alone [10] . This trial demonstrated 14% improvement in OS at 5-years but with only a trend toward statistical significance in the NAC cohort (P ¼ 0.06) [10] . In addition, three separate meta-analyses composed of around 3000 patients each showed statistically significant absolute improvements in 5-year OS between 5 and 6.5% [11] [12] [13] . Currently, based on existing data, there is strong evidence to support NAC using a cisplatin-based combination in patients with MIBC.
However, chemotherapy also carries the risk of significant toxicities. The SWOG 8710 reported that 73% of patients exposed to MVAC experienced more than grade 3 toxicities [10] . Attempts to find similarly effective regimens with less toxicity have been undertaken, such as the high-dose MVAC (HD-MVAC) regimen administered every two weeks with growth factor support [3] . Research has also focused on combination chemotherapy with carboplatin, which is a less toxic platinum alternative. The existing evidence for the use of carboplatin-based regimens comes from small retrospective as well as prospective trials that are underpowered and demonstrate no significant difference in pathologic or survival outcomes compared with MVAC [15] [16] [17] [18] [19] [20] . Therefore, the routine use of carboplatin-based regimens is not recommended at this time.
There are many controversies surrounding NAC. One controversy pertains to optimal patient selection. There is an argument to reserve NAC for patients with higher stage disease as absolute OS benefit with NAC tends to be greater in those with at least T3 disease [6, 10, 12] . In addition, there are proponents who would argue that within the clinical T2 (cT2) cohort, NAC should be reserved for patients with higher risk features such as those with presence of hydronephrosis and/or lymphovascular invasion [21, 22] . However, clinical staging is inaccurate with 43-70% of cT2 patients being upstaged on final pathology review [23] [24] [25] [26] . Thus, excluding all cT2 patients from NAC could result in denying some higher risk patients treatment.
Another debate revolves around the optimal NAC regimen. The use of MVAC or cisplatin, methotrexate, and vinblastine is considered a gold standard [9, 10] . However, these regimens have been associated with unfavorable toxicity profile such as severe neutropenia, mucositis, renal, and cardiac toxicity, as well as toxic death rate of 3-4% [9, 10] . In a trial of gemcitabine and cisplatin compared with MVAC, von der Maase et al. [27] reported similar efficacy and better tolerability with the use of gemcitabine and cisplatin compared with MVAC in patients with metastatic disease. Many oncologists extrapolated these data to the neoadjuvant setting [28 & ]. However, the use of gemcitabine and cisplatin has not been prospectively studied in a randomized fashion and most of the evidence for its use in neoadjuvant setting comes from small single center retrospective studies or prospective case series [29 & ]. Although there is no strong evidence suggesting increased surgical complication rates in those receiving NAC, there has been an argument that patients may be unnecessarily subjected to delays in definitive local therapy if they receive NAC that ends up being ineffective [3, 10, [30] [31] [32] . Unfortunately, there are currently no good tools to predict response to NAC [33] . Although some clinicians may employ repeat imaging or cystoscopy assessment, these are imperfect tests. Thus, failure to be able to predict who will most benefit from NAC remains one of the most important reasons to argue against its routine use.
An alternate strategy to NAC is adjuvant chemotherapy administered after radical cystectomy. Despite a lack of strong data supporting clinical efficacy associated with adjuvant chemotherapy use, large multiinstitutional reviews from the USA and Europe demonstrate that more patients tend to receive adjuvant chemotherapy compared with NAC [34, 35] . The existing evidence for the use of adjuvant chemotherapy is best summarized by the Advanced Bladder Cancer Meta-analysis collaboration study, which pooled six randomized controlled trials with 491 patients and demonstrated 25% relative reduction in the risk of death with absolute improvement in OS of 9% at 3 years [36, 37] . However, these conclusions are limited by
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the quality of the data used to perform the analysis. Perceived advantages of adjuvant chemotherapy include immediate definitive local therapy, lack of overtreatment of patients with good risk pathology, and that therapy could be tailored to individualized pathology [38] . Disadvantages of adjuvant chemotherapy are that it delays administering systemic therapy to deal with potential micrometastases and some patients have delayed postoperative healing such that they never have the chance to receive adjuvant chemotherapy. Finally, similar to NAC, there is no definitive way to know, which patient will benefit [38] .
Despite the existing evidence suggesting that perioperative chemotherapy should be the standard of care in MIBC population, the reported concordance with clinical practice guidelines is estimated to be around 11. 
REVIEW OF STUDIES

Effectiveness of perioperative chemotherapy
To compare the reported efficacy of NAC to its clinical effectiveness in Canada, Booth et al. [43 && ] undertook an Ontario-based retrospective study aimed at evaluating the external validity of the clinical trial results for administration of perioperative chemotherapy. This retrospective analysis looked at 2044 patients who underwent definitive therapy for MIBC between 1994 and 2008. The reported 5-year OS of patients who received NAC was 26%. This differs from reported 5-year OS rates from published trials that ranges from 49 to 57% [10, 14] . However, they did demonstrate that OS in the group receiving perioperative chemotherapy was superior to the group that did not receive it.
Neoadjuvant chemotherapy
The emerging platinum-based alternatives There have been two recent prospective multicenter phase II trials that investigated the efficacy of ], the authors enrolled 39 patients with clinical T2-T4 N0-1 M0 MIBC. Patients were treated with four cycles of HD-MVAC followed by radical cystectomy. This trial found that 49% of patients achieved pathologic down staging with one-year disease-free survival (DFS) of 89%. Of particular importance is that 26% of patients achieved complete pT0 rate, and only 10% of patients experienced high-grade toxicity with no episodes of treatment-related death. Despite the small number of patients enrolled, these trials suggest that HD-MVAC achieves similar pT0 rates to standard 12-week MVAC regimen with lower rate of high-grade toxicities.
As the existing evidence for the use of gemcitabine and cisplatin as a neoadjuvant regimen is confined to small retrospective single center trials or case series, there are two-registered phase III trials attempting to compare neoadjuvant gemcitabine and cisplatin with HD-MVAC [46, 48] . One trial is being conducted by University Hospital in Rouen, France [49] , whereas the second study is led by the SWOG group in the USA [48] . The results from these studies aim to provide higher quality evidence for the use of gemcitabine and cisplatin in the neoadjuvant setting.
Effect of neoadjuvant chemotherapy on surgical outcomes
One of the reported limitations of the use of NAC is the perceived risk of adverse perioperative outcomes. To specifically investigate the effect of NAC on perioperative outcomes in patients who underwent radical cystectomy, Gandaglia et al. ] investigated the clinical outcomes following neoadjuvant cisplatin-based chemotherapy in the elderly to determine whether age is a factor in determining tolerance and response to chemotherapy. This was a single institution retrospective case series analysis of 83 patients with median age of 68 with T2-T4a N0M0 TCC who were treated with gemcitabine and cisplatin between 2005 and 2011. Overall, the study found that elderly patients with good functional status and limited comorbidities have similar outcomes to their younger counterparts receiving NAC. ] have reported on whether a riskadapted approach can be used to select higher risk patients for NAC, thus, sparing low-risk patients from toxicity. This was a single center retrospective analysis of 1285 patients who underwent radical cystectomy between 2000 and 2010. The presence of high-risk features was defined as the presence of hydroureteronephrosis, clinical T3b-T4a disease, and/or histological evidence of lymphovascular invasion. Overall, patients in the high-risk group had statistically worse 5-year OS, PFS, and diseasespecific survival, and when compared with low-risk patients (P < 0.001). However, within the low-risk cohort, 49.2% of patients had pathological upstaging of their disease, underscoring the problems of clinical staging. Given the challenges in clinical staging and the high rate of being upstaged at final pathology, this risk-adapted approach has not been widely adopted.
Adjuvant chemotherapy
To further improve the statistical power of the existing data on cisplatin-based adjuvant chemotherapy, Loew et al. [53 & ], conducted an updated metaanalysis from nine randomized clinical control trials, which demonstrated a statistically significant benefit in OS and DFS specifically in patients with lymph-node-positive disease.
The largest prospective trial for adjuvant chemotherapy is the EORTC 30994 trial published by Sternberg et al. [54 && ] in December 2014. This was a large open label, multicenter randomized phase III trial, which planned to recruit 660 patients with pathologic T3-T4 or NþM0 TCC to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy and bilateral pelvic lymph node dissection. In this trial, which was terminated early, only 284 participants were accrued between 2008 and 2010. Patients were randomized to either four cycles of adjuvant chemotherapy within 90 days of surgery (gemcitabine and cisplatin, MVAC, or HD-MVAC based on institutional preference) or six cycles of chemotherapy at relapse. Overall, administration of immediate adjuvant chemotherapy did not lead to significant improvement in OS (P ¼ 0.13), but was associated with significant improvement in prolonging 5-year PFS. Unfortunately, this trial was limited by a small sample size and was underpowered to detect an OS difference.
In the context of existing evidence, these articles strengthen the role of adjuvant chemotherapy in MIBC. However, to improve the quality of the available data and provide better guidance to clinicians, future trials should focus on an individualized patient data meta-analysis to better elucidate the benefit of adjuvant chemotherapy in this setting. 
Guideline concordance
Novel approaches
There are currently multiple phase II trials investigating the role of targeted therapy in the perioperative setting [46] . Interesting results have been seen with the use of erlotinib [57] , and dasatinib [58, 59] monotherapy preradical cystectomy, and with bevacizumab [60] and sunitinib [61] in combination with cisplatin-based chemotherapy. However, to firmly delineate the potential benefit of these agents we need to await phase III clinical trials.
CONCLUSION
The role of perioperative chemotherapy for MIBC has been well established with the strongest literature in support of NAC. The optimal regimen is not known but cisplatin-based combination therapy should be the standard. Although perioperative chemotherapy use is still low, it is encouraging to see a trend toward increased use of chemotherapy in this setting. And increased adherence to clinical practice guidelines. Future research will need to focus on how to manage cisplatin ineligible patients and explore how new therapeutic agents, such as molecular and immune-targeted therapies and biologics, may play a role in the MIBC-patient population.
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